Works about SUBSTANTIA nigra

Results: 2604
    1
    2
    3
    4

    Randomized, double-blind, placebo-controlled pilot study of metformin as an adjunctive therapy in Parkinson's disease.

    Published in:
    Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1497261
    By:
    • AlRasheed, Hayam Ali;
    • Bahaa, Mostafa M.;
    • Elmasry, Thanaa A.;
    • Elberri, Eman I.;
    • Kotkata, Fedaa A.;
    • El Sabaa, Ramy M.;
    • Elmorsi, Yasmine M.;
    • Kamel, Mostafa M.;
    • Negm, Walaa A.;
    • Hamouda, Amir O.;
    • Aldossary, Khlood Mohammad;
    • Salahuddin, Muhammed M.;
    • Yasser, Mohamed;
    • Eldesouqui, Mamdouh;
    • Hamouda, Manal A.;
    • Eltantawy, Nashwa;
    • Elawady, Mirna E.;
    • Abdallah, Mahmoud S.
    Publication type:
    Article
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35

    <sup>18</sup>F-PI-2620 Tau PET is associated with cognitive and motor impairment in Lewy body disease.

    Published in:
    Brain Communications, 2025, v. 7, n. 1, p. 1, doi. 10.1093/braincomms/fcae458
    By:
    • Winer, Joseph R;
    • Vossler, Hillary;
    • Young, Christina B;
    • Smith, Viktorija;
    • Romero, America;
    • Shahid-Besanti, Marian;
    • Abdelnour, Carla;
    • Wilson, Edward N;
    • Anders, David;
    • Morales, Aimara Pacheco;
    • Andreasson, Katrin I;
    • Yutsis, Maya V;
    • Henderson, Victor W;
    • Davidzon, Guido A;
    • Mormino, Elizabeth C;
    • Poston, Kathleen L
    Publication type:
    Article
    36

    Biallelic NDUFA13 variants lead to a neurodevelopmental phenotype with gradual neurological impairment.

    Published in:
    Brain Communications, 2025, v. 7, n. 1, p. 1, doi. 10.1093/braincomms/fcae453
    By:
    • Kaiyrzhanov, Rauan;
    • Thompson, Kyle;
    • Efthymiou, Stephanie;
    • Mukushev, Askhat;
    • Zharylkassyn, Akbota;
    • Prasad, Chitra;
    • Karimiani, Ehsan Ghayoor;
    • Alvi, Javeria Raza;
    • Niyazov, Dmitriy;
    • Alahmad, Ahmad;
    • Babaei, Meisam;
    • Tajsharghi, Homa;
    • Albash, Buthaina;
    • Alaqeel, Ahmad;
    • Charif, Majida;
    • Hashemi, Narges;
    • Heidari, Morteza;
    • Kalantar, Seyed Mehdi;
    • Lenaers, Guy;
    • Mehrjardi, Mohammad Yahya Vahidi
    Publication type:
    Article
    37
    38

    Clinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [<sup>18</sup>F]FE-PE2I PET: independent validation with new insights.

    Published in:
    Brain Communications, 2024, v. 6, n. 5, p. 1, doi. 10.1093/braincomms/fcae345
    By:
    • Honhar, Praveen;
    • Sadabad, Faranak Ebrahimian;
    • Tinaz, Sule;
    • Gallezot, Jean-Dominique;
    • Dias, Mark;
    • Naganawa, Mika;
    • Yang, Yanghong;
    • Henry, Shannan;
    • Hillmer, Ansel T;
    • Gao, Hong;
    • Najafzadeh, Soheila;
    • Comley, Robert;
    • Nabulsi, Nabeel;
    • Huang, Yiyun;
    • Finnema, Sjoerd J;
    • Carson, Richard E;
    • Matuskey, David
    Publication type:
    Article
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48

    IGF2 prevents dopaminergic neuronal loss and decreases intracellular alpha-synuclein accumulation in Parkinson's disease models.

    Published in:
    Cell Death Discovery, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41420-023-01734-1
    By:
    • Arcos, Javiera;
    • Grunenwald, Felipe;
    • Sepulveda, Denisse;
    • Jerez, Carolina;
    • Urbina, Valentina;
    • Huerta, Tomas;
    • Troncoso-Escudero, Paulina;
    • Tirado, Daniel;
    • Perez, Angela;
    • Diaz-Espinoza, Rodrigo;
    • Nova, Esteban;
    • Kubitscheck, Ulrich;
    • Rodriguez-Gatica, Juan Eduardo;
    • Hetz, Claudio;
    • Toledo, Jorge;
    • Ahumada, Pablo;
    • Rojas-Rivera, Diego;
    • Martín-Montañez, Elisa;
    • Garcia-Fernandez, María;
    • Vidal, René L.
    Publication type:
    Article
    49
    50